Art. -Nr.: HY-B0265

Nimodipine

(Synonyms: BAY-e 9736)

21 Cited Publications

Kundenbewertung

Based on 21 publication(s) in Google Scholar

Nimodipine (BAY-e 9736) is an orally active, well-tolerated and light-sensitive dihydropyridine calcium antagonist. Nimodipine can be used for the research of cerebrovascular disorders.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.86%
CAS. Nr.: 66085-59-4
Formel: C₂₁H₂₆N₂O₇
Molecular Weight:418.44

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Nimodipine Chemical Structure

CAS. Nr.: 66085-59-4

Größe

Preis

Verfügbarkeit

Menge

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Massenanfrage

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (21)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Bioz

Biologische Aktivität

Beschreibung

Nimodipine (BAY-e 9736) is an orally active, well-tolerated and light-sensitive dihydropyridine calcium antagonist. Nimodipine can be used for the research of cerebrovascular disorders^[1].

IC₅₀ & Target

dihydropyridine calcium^[1]

Alle Calcium Channel Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	EC₅₀	0.8 μM Compound: 54	Agonist activity at mouse TRPA1 channel expressed in CHO cells assessed as increase in intracellular calcium influx Agonist activity at mouse TRPA1 channel expressed in CHO cells assessed as increase in intracellular calcium influx	[PMID: 20356305]
HEK293	IC₅₀	0.11 μM Compound: Nimodipine	Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit	[PMID: 22761000]
HepG2	EC₅₀	0.39 μM Compound: 5	Agonist activity at PXR (unknown origin) expressed in human HepG2 cells assessed as induction of CYP3A4 transactivation after 16 hrs by luciferase reporter gene assay Agonist activity at PXR (unknown origin) expressed in human HepG2 cells assessed as induction of CYP3A4 transactivation after 16 hrs by luciferase reporter gene assay	[PMID: 23688559]
LLC-MK2	IC₅₀	32.31 μM Compound: Nimodipine	Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi infected in rhesus monkey LLC-MK2 cells after 48 hrs by MTT assay Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi infected in rhesus monkey LLC-MK2 cells after 48 hrs by MTT assay	[PMID: 20934347]
LLC-MK2	IC₅₀	96.19 μM Compound: Nimodipine	Cytotoxicity against rhesus monkey LLC-MK2 cells after 48 hrs by MTT assay Cytotoxicity against rhesus monkey LLC-MK2 cells after 48 hrs by MTT assay	[PMID: 20934347]
PC-12	EC₅₀	1.29 μg/mL Compound: Nimodipine	Anti-anoxic activity in rat PC12 cells reduction in assessed as sodium hydrosulfite-induced cell injury Anti-anoxic activity in rat PC12 cells reduction in assessed as sodium hydrosulfite-induced cell injury	[PMID: 31317731]
PC-12	EC₅₀	97.3 μM Compound: Nimodipine	Neuroprotective activity against glutamate-induced neuronal cell death in rat PC12 cells assessed as increase in cell viability pretreated for 2 hrs followed by glutamate challenge measured after 24 hrs by MTT assay Neuroprotective activity against glutamate-induced neuronal cell death in rat PC12 cells assessed as increase in cell viability pretreated for 2 hrs followed by glutamate challenge measured after 24 hrs by MTT assay	[PMID: 29775304]
SH-SY5Y	IC₅₀	14 μM Compound: Nimodipine	Inhibition of K+-induced voltage gated calcium channel opening in human SH-SY5Y cells assessed as decrease in Ca2+ level after 10 mins by Fluo-4 dye-based fluorescence assay Inhibition of K+-induced voltage gated calcium channel opening in human SH-SY5Y cells assessed as decrease in Ca2+ level after 10 mins by Fluo-4 dye-based fluorescence assay	[PMID: 30530190]
Ventricular myocyte	IC₅₀	0.3 μM Compound: Nimodipine	Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes	[PMID: 22761000]

In Vitro

Nimodipine (1.5~150 μg/ml; 15 minutes; B16a and W256 cells) results in a dose-dependent inhibition of B16a and W256 tumor-cell-induced platelet aggregation. Nimodipine is also inhibitory in a homologous system^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Nimodipine (0.2 μg/μl, intrathecal administration) prevents subarachnoid hemorrhage-associated cerebral vasospasm by prophylactic continuous intrathecal administration^[2].
Nimodipine(0.1~80 mg/kg; p.o.) results in a significant dose-dependent inhibition of spontaneous metastasis^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

New Zealand white rabbits^[2]
Dosage:

0.2 µg/µl
Administration:

Intrathecal administration
Result:

Prevented subarachnoid hemorrhage-associated cerebral vasospasm by prophylactic continuous intrathecal administration.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 66085-59-4
Appearance Solid
Molecular Weight 418.44
Formel C₂₁H₂₆N₂O₇
Color Light yellow to yellow
SMILES

O=C(C1=C(C)NC(C)=C(C(OC(C)C)=O)C1C2=CC=CC([N+]([O-])=O)=C2)OCCOC
Synonyms

BAY-e 9736
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (21)

All In Vivo Efficacy StudyHistological Imaging/Staining

Sort by:

Journal Impact Factor

Adv Healthc Mater

A Novel Targeted Nanoparticle for Traumatic Brain Injury Treatment: Combined Effect of ROS Depletion and Calcium Overload Inhibition. [Abstract]

2022 Jun;11(11):e2102256. PMID: 35118827
Proc Natl Acad Sci U S A

Endogenous ATP-powered nanomotors directing neural stem cell differentiation for Parkinson's disease treatment. [Abstract]

2026 Mar 31;123(13):e2520119123. PMID: 41880568
Phytomedicine

Shenqi granules enhance recovery from cerebral ischemia-reperfusion injury by modulating tryptophan and tyrosine metabolism and activating NFE2L2/NRF2. [Abstract]

2025 May:140:156623. PMID: 40068292
Aging Cell

Upregulation of the Cav1.3 channel in inner hair cells by interleukin 6-dependent inflammaging contributes to age-related hearing loss. [Abstract]

2024 Aug 15:e14305. PMID: 39148148

Nimodipine purchased from MedChemExpress. Usage Cited in: Aging Cell. 2024 Aug 15:e14305. [Abstract]

Timeline for ABR testing and drug treatment. Nimodipine was administered subcutaneously to 7-month-old WT mice at a dose of 5 mg/kg or 10 mg/kg every other day for 60 days.

Nimodipine purchased from MedChemExpress. Usage Cited in: Aging Cell. 2024 Aug 15:e14305. [Abstract]

Timeline for ABR testing and drug treatment. Nimodipine was administered subcutaneously to 7-month-old WT mice at a dose of 5 mg/kg or 10 mg/kg every other day for 60 days. Representative ABR waveforms in response to click stimuli (90-30 dB) in mice.

Nimodipine purchased from MedChemExpress. Usage Cited in: Aging Cell. 2024 Aug 15:e14305. [Abstract]

Timeline for ABR testing and drug treatment. Nimodipine was administered subcutaneously to 7-month-old WT mice at a dose of 5 mg/kg or 10 mg/kg every other day for 60 days. ABR threshold to click stimuli in the AHL, solvent, and Nimodipine (5, 10 mg/kg) treatment groups.

Nimodipine purchased from MedChemExpress. Usage Cited in: Aging Cell. 2024 Aug 15:e14305. [Abstract]

Timeline for ABR testing and drug treatment. Nimodipine was administered subcutaneously to 7-month-old WT mice at a dose of 5 mg/kg or 10 mg/kg every other day for 60 days. ABR threshold to pure-tone in the AHL, solvent, and Nimodipine (5, 10 mg/kg) treatment groups.

Nimodipine purchased from MedChemExpress. Usage Cited in: Aging Cell. 2024 Aug 15:e14305. [Abstract]

Immunofluorescence of IHCs and ribbon synapses in the apex, middle, and base of cochlea from WT 9 M mice, solvent-treated, and Nimodipine (5, 10 mg/kg)-treated mice.
Antioxid Redox Signal

Nimodipine Blocks Histone-Induced Calcium Overload to Protect Neurons after Traumatic Brain Injury. [Abstract]

2025 Sep 17. PMID: 40960921
J Ethnopharmacol

Harpagide from radix scrophulariae attenuated ischemic stroke injury through calcium homeostasis regulation between mitochondria-associated membranes via the IP3R1/GRP75/VDAC1 complex. [Abstract]

2025 Jun 13:120147. PMID: 40517916
Front Pharmacol

Nimodipine Promotes Functional Recovery After Spinal Cord Injury in Rats. [Abstract]

2021 Sep 13:12:733420. PMID: 34594224
Int Immunopharmacol

Shikonin improves cerebral ischemia-reperfusion injury by regulating astrocyte polarization through ERK1/2-SP1-SLC7A10. [Abstract]

2025 Dec 8:169:115957. PMID: 41365200
J Med Virol

Influenza A Virus Induces Autophagosome by Inhibiting LTCC/Calpain 2/LC3A Signaling to Promote Viral Replication. [Abstract]

2025 May;97(5):e70393. PMID: 40358023
J Physiol

Chronic exercise increases excitability of lamina X neurons through enhancement of persistent inward currents and dendritic development in mice. [Abstract]

2022 Aug;600(16):3775-3793. PMID: 35848453
Eur J Cell Biol

The mechanical mechanism of angiotensin II induced activation of hepatic stellate cells promoting portal hypertension. [Abstract]

2024 May 28;103(2):151427. PMID: 38820882
Front Cell Neurosci

Three-Week Treadmill Exercise Enhances Persistent Inward Currents, Facilitates Dendritic Plasticity, and Upregulates the Excitability of Dorsal Raphe Serotonin Neurons in ePet-EYFP Mice. [Abstract]

2020 Oct 16;14:575626. PMID: 33177992
ACS Chem Neurosci

Poliumoside Exhibits Neuroprotective Effects against Cerebral Ischemia-Reperfusion Injury by Relieving Microglia-Mediated Neuronal Damage and Astrocytic Activation. [Abstract]

2025 Apr 28. PMID: 40295176
Mol Med Rep

Eupafolin alleviates cerebral ischemia/reperfusion injury in rats via blocking the TLR4/NF‑κB signaling pathway. [Abstract]

2020 Dec;22(6):5135-5144. PMID: 33173992
Chem Biol Drug Des

Forsythiaside A Ameliorates Oxidative Damage Caused by Cerebral Ischemia Through the Nrf2/HO-1 Signaling Pathway. [Abstract]

2025 Mar;105(3):e70083. PMID: 40035314
Front Neural Circuits

Serotonergic Modulation of Persistent Inward Currents in Serotonergic Neurons of Medulla in ePet-EYFP Mice. [Abstract]

2021 Apr 6:15:657445. PMID: 33889077
Neuroscience

TGF-β1 Protects Trauma-injured Murine Cortical Neurons by Upregulating L-type Calcium Channel Cav1.2 via the p38 Pathway. [Abstract]

2022 Jun 1;492:47-57. PMID: 35460836
Neurosci Res

Inhibition of calcium-sensing receptors improves intestinal motility in obese mice through enteric neurons and vagal center. [Abstract]

2025 Dec 13:223:105008. PMID: 41397659
J Neurophysiol

Sequential activation of multiple persistent inward currents induces staircase currents in serotonergic neurons of medulla in ePet-EYFP mice. [Abstract]

2020 Jan 1;123(1):277-288. PMID: 31721638
J Stroke Cerebrovasc Dis

Shikonin attenuates cerebral ischemia/reperfusion injury via inhibiting NOD2/RIP2/NF-κB-mediated microglia polarization and neuroinflammation. [Abstract]

2024 Jun;33(6):107689. PMID: 38527567
SSRN

2023 Sep 7.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (238.98 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3898 mL

11.9491 mL

23.8983 mL

5 mM

0.4780 mL

2.3898 mL

4.7797 mL

10 mM

0.2390 mL

1.1949 mL

2.3898 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.97 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.97 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Portuguese - PT (392 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Langley, M.S., et al. Nimodipine. Drugs 37, 669–699 (1989).

[2]. Marbacher S, et al. Prevention of delayed cerebral vasospasm by continuous intrathecal infusion of glyceroltrinitrate and nimodipine in the rabbit model in vivo. Intensive Care Med. 2008;34(5):932-938. [Content Brief]

[3]. Honn KV, et al. Inhibition of tumor cell-platelet interactions and tumor metastasis by the calcium channel blocker, nimodipine. Clin Exp Metastasis. 1984;2(1):61-72. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.3898 mL	11.9491 mL	23.8983 mL	59.7457 mL
	5 mM	0.4780 mL	2.3898 mL	4.7797 mL	11.9491 mL
	10 mM	0.2390 mL	1.1949 mL	2.3898 mL	5.9746 mL
	15 mM	0.1593 mL	0.7966 mL	1.5932 mL	3.9830 mL
	20 mM	0.1195 mL	0.5975 mL	1.1949 mL	2.9873 mL
	25 mM	0.0956 mL	0.4780 mL	0.9559 mL	2.3898 mL
	30 mM	0.0797 mL	0.3983 mL	0.7966 mL	1.9915 mL
	40 mM	0.0597 mL	0.2987 mL	0.5975 mL	1.4936 mL
	50 mM	0.0478 mL	0.2390 mL	0.4780 mL	1.1949 mL
	60 mM	0.0398 mL	0.1992 mL	0.3983 mL	0.9958 mL
	80 mM	0.0299 mL	0.1494 mL	0.2987 mL	0.7468 mL
	100 mM	0.0239 mL	0.1195 mL	0.2390 mL	0.5975 mL

Keywords

Nimodipine

21 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Nimodipine

Membrane Transporter/Ion Channel Compound Library

Neuronal Signaling Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Autophagy Compound Library

Drug Repurposing Compound Library

Anti-Cardiovascular Disease Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Neuroprotective Compound Library

Drug-Induced Liver Injury (DILI) Compound Library

Rare Diseases Drug Library

Calcium Channel Blocker Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Off-patent Drug Library

Antihypertensive Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cell Death Library

Ion Channel Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Nimodipine

Alle Calcium Channel Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (21)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Nimodipine Related Classifications

Art. -Nr.: HY-B0265